Natera, Inc. (NASDAQ:NTRA) Insider John Fesko Sells 1,438 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 1,438 shares of the business's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $156.85, for a total value of $225,550.30. Following the completion of the transaction, the insider directly owned 153,799 shares in the company, valued at approximately $24,123,373.15. This represents a 0.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

John Fesko also recently made the following trade(s):

• On Monday, July 21st, John Fesko sold 339 shares of Natera stock. The shares were sold at an average price of $139.29, for a total value of $47,219.31.

Natera Trading Up 2.4%

Natera stock traded up $3.25 on Thursday, hitting $141.07. 1,421,449 shares of the stock traded hands, compared to its average volume of 1,212,550. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00. The firm has a market cap of $19.26 billion, a P/E ratio of -95.97 and a beta of 1.73. The business's fifty day simple moving average is $159.24 and its 200 day simple moving average is $157.55.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. During the same quarter last year, the company earned ($0.56) EPS. The firm's revenue for the quarter was up 36.5% on a year-over-year basis. As a group, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently bought and sold shares of the business. LRI Investments LLC purchased a new position in Natera in the fourth quarter worth about $29,000. Bank of Jackson Hole Trust bought a new position in shares of Natera in the 1st quarter worth approximately $29,000. Rakuten Securities Inc. boosted its holdings in shares of Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after buying an additional 119 shares during the last quarter. ORG Partners LLC bought a new stake in Natera during the first quarter valued at approximately $32,000. Finally, TCTC Holdings LLC grew its position in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after buying an additional 124 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. UBS Group increased their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Piper Sandler lifted their price objective on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Barclays increased their target price on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Finally, Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.